Omnicell, Inc. is recognized as a leader in transforming the pharmacy and nursing care delivery model.
The company is committed to addressing the critical challenges inherent in medication management and elevating the role of clinicians within healt…
Analysis
Middle-of-the-road
Omnicell, Inc. is a middle-of-the-road business: neither the economics nor the price stand out from the peer group.
The price is expensive. You pay 175.1× its owner earnings: the cash an owner could take out each year, which is in the historically expensive zone. At today's price, the market is assuming roughly 36% yearly growth; analysts expect 30%. The gap between price and consensus is worth watching: demanding expectations.
The trajectory is moderate and the balance sheet is sturdy. The company scores 12/20 on our value-creation score: creating some value. Analysts lean positive.
Nothing is flagged here: no red or amber gates, no divergence between profits and cash. That is itself information: the numbers are straightforward. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Jan 202389
91
2023202420252026
All-time high
91
Jun 2026
All-time low
4
Jan 2025
Average rank
54
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
66
72
78
46
Price/Earnings
24
59
61
40
Price/Book
62
79
79
19
Dividend Yield
1
1
1
1
Value (overall)
48
76
81
76
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.